Roche buys Mirus in $125M deal

Roche is continuing its buying spree with a deal to acquire Madison, WI-based Mirus Bio for $125 million. Mirus specializes in developing nucleic acid-based therapies, which includes RNAi technology for gene silencing.

"The technology brought by Mirus, together with additional technologies, will bring us closer to creating fully-enabled RNAi therapeutics," said Lee Babiss, global head of Roche pharma research.

- check out the release
- read the report from Hays Pharma

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.